Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€21.13

€21.13

-2.160%
-0.465
-2.160%
€31.98
 
25.07.25 / Tradegate WKN: 852009 / Symbol: PFE / Name: Pfizer / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Pfizer Inc. is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Pfizer

sharewise wants to provide you with the best news and tools for Pfizer, so we directly link to the best financial data sources.

News

Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound: https://www.marketbeat.com/logos/articles/med_20250722153159_healthcare-stocks-hit-valuation-bottom-3-names-to.jpg
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound

Today’s stock market focus is centered on one single sector: technology stocks.

The excitement around artificial intelligence (AI) has led to most attention—and capital–being concentrated in one

Top 5 Undervalued Dividend Stocks With Strong Payout Potential: https://www.marketbeat.com/logos/articles/med_20250707092446_top-5-undervalued-dividend-stocks-with-strong-payo.png
Top 5 Undervalued Dividend Stocks With Strong Payout Potential

In a market where mega-cap growth and tech stocks continue to dominate headlines and stretch valuations, income-oriented investors may feel sidelined. But for those with a long-term perspective

Pfizer's 7.5% Dividend: Income Haven or House of Cards?: https://www.marketbeat.com/logos/articles/med_20250522132523_pfizers-7.jpg
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
[content-module:CompanyOverview|NYSE:PFE]

A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income-seeking

Pfizer Stock: Billion-Dollar Chinese Cancer Drug Deal
Pfizer Stock: Billion-Dollar Chinese Cancer Drug Deal

Pharmaceutical giant Pfizer is making significant strategic moves in oncology, investing up to $6 billion in a licensing deal with Chinese biotech firm 3SBio. The agreement centers on SSGJ-707, a

Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY
Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY
[content-module:CompanyOverview|NYSE:LLY]

The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), is back in the green in 2025 as of the Apr. 21 close. Shares were down

2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention to the motives behind the decision as it can signal a shift in

Pfizer Stock: Probe Into COVID Vaccine Timing Claims
Pfizer Stock: Probe Into COVID Vaccine Timing Claims

Pfizer shares are facing significant pressure following reports that Manhattan federal prosecutors are investigating serious allegations. The inquiry centers on claims made by British pharmaceutical

Pfizer Stock: Company Sells Entire Haleon Stake
Pfizer Stock: Company Sells Entire Haleon Stake

Pharmaceutical giant Pfizer has divested its complete shareholding in consumer health company Haleon for approximately £2.5 billion ($3.24 billion). The transaction was executed at 385 pence per

Pfizer Stock: Shares Drop Despite Cancer Drug Progress
Pfizer Stock: Shares Drop Despite Cancer Drug Progress

Pfizer's stock fell 1.7% to $26.20 in Tuesday afternoon trading on the New York Stock Exchange, despite the company announcing promising results from a key clinical trial. The decline came amid

Pfizer Stock: Nearing 52-Week Lows Amid Challenges
Pfizer Stock: Nearing 52-Week Lows Amid Challenges

Pfizer's stock currently faces a challenging market position, trading precariously close to its 52-week lows. The shares recently showed minimal recovery, rising just 0.2 percent to $25.99 in New

Pfizer Stock: Court Ruling Clouds Positive Momentum
Pfizer Stock: Court Ruling Clouds Positive Momentum

Pfizer shares gained 0.9 percent on Wednesday in New York trading, closing at $25.98 after reaching an intraday high of $26.17. Investor interest remained strong with over one million shares

Pfizer Stock: Cancer Drug Study Shows Promising Results
Pfizer Stock: Cancer Drug Study Shows Promising Results

Pfizer and Astellas Pharma have achieved a significant breakthrough in advanced bladder cancer treatment, demonstrating remarkable success with their combination therapy of PADCEV and KEYTRUDA. The

Pfizer Stock: Quarterly Results Show Strong Recovery Signs
Pfizer Stock: Quarterly Results Show Strong Recovery Signs

Pfizer's recent quarterly performance demonstrates a significant turnaround, with revenues surging nearly 25% to reach $17.76 billion. The pharmaceutical giant has shown remarkable improvement in

Pfizer Stock: Q4 Surge Despite Market Dip
Pfizer Stock: Q4 Surge Despite Market Dip

Pfizer's stock experienced a modest decline of 0.8% to $26.24 in Thursday's New York trading session, yet the pharmaceutical giant's underlying performance tells a more compelling story. The company

Pfizer Stock: AI Partnership Drives Strategic Transformation
Pfizer Stock: AI Partnership Drives Strategic Transformation

Pharmaceutical giant Pfizer is embarking on a significant strategic shift with a heightened focus on artificial intelligence through a multi-year collaboration with technology firm Data4Cure. This

Pfizer Stock: Cancer Drug Study Shows Promising Results
Pfizer Stock: Cancer Drug Study Shows Promising Results

Pfizer's recent breakthrough in cancer research is painting a promising picture for the pharmaceutical giant, despite its stock experiencing a slight dip of 0.9% to $26.27. The company has achieved

2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade: https://g.foolcdn.com/editorial/images/824342/doctor-and-patient-talking.jpg
2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade

Pharmaceutical giants Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) have lagged the market over the past year, although Pfizer's poor performance dates back much further. Though these companies

Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead?: https://g.foolcdn.com/editorial/images/825600/21_05_25-a-sign-with-the-word-dividends-next-to-a-money-roll-_gettyimages-186201544.jpg
Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead?

One of the big reasons to like Pfizer (NYSE: PFE) today is its huge 7.1% dividend yield. To put that yield into context, the S&P 500 index is yielding roughly 1.3% and the average healthcare stock a

2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 Right Now: https://g.foolcdn.com/editorial/images/825475/a-person-delivering-a-presentation-getty.jpg
2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 Right Now

If putting your money to work on Wall Street is something you haven't started doing because it feels like a rich person's game and you're not one, I've got good news. Discount brokerages no longer

This Once-Dominant Healthcare Stock Down 50% Is Finally Ready for a Comeback: https://g.foolcdn.com/editorial/images/824348/gettyimages-research-team-smiles-in-lab.jpg
This Once-Dominant Healthcare Stock Down 50% Is Finally Ready for a Comeback

A few years ago, Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. The pharma giant recorded a record of $100 billion in sales back in 2022, and saw

3 Disappointing Blue Chip Stocks That Have Crashed as Much as 87% in 10 Years: https://g.foolcdn.com/editorial/images/824008/frustrated-investor-looking-at-stocks.jpg
3 Disappointing Blue Chip Stocks That Have Crashed as Much as 87% in 10 Years

Normally, a buy-and-hold strategy pays off, and investors expect to see strong gains from their investments. The S&P 500 (SNPINDEX: ^GSPC) has risen by 200% over the past decade, and mirroring the

2 Stocks to Buy With Less Than $50: https://g.foolcdn.com/editorial/images/823373/physician-talking-to-patient.jpg
2 Stocks to Buy With Less Than $50

One formula to generate strong returns on equity markets involves investing small amounts of money in top stocks regularly over long periods. Buying fractional shares is one way to apply this

Is Pfizer Stock a Yield Trap?: https://g.foolcdn.com/editorial/images/823371/investor-checking-stocks-getty.jpg
Is Pfizer Stock a Yield Trap?

When it comes to your hard-earned money, you have a lot of choices about where to spend it. If your physician prescribes a new branded drug, though, you and your insurance company have few options.

2 Top Stocks to Buy With Less Than $30: https://g.foolcdn.com/editorial/images/821726/pharmacist-talking-to-patient.jpg
2 Top Stocks to Buy With Less Than $30

Though wealthy and successful investors garner much attention on Wall Street, equity markets are accessible to the average person. That's one of the great things about investing in stocks. Even with

Why I Just Bought More of This Beaten-Down 7%-Yielding Dividend Stock: https://g.foolcdn.com/editorial/images/821870/dividend-laptop.jpg
Why I Just Bought More of This Beaten-Down 7%-Yielding Dividend Stock

Pick a time frame -- year to date, last 12 months, last three years, last five years, or last 10 years. Regardless of which you choose, Pfizer's (NYSE: PFE) share price has declined during the